Zynerba Pharmaceuticals (Nasdaq:ZYNE) is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments. It has a market cap of $83.3 million, and is not profitable.. Guest Devin Shutte from The Robert Group and resident expert Paul Theron from Vestact decide whether Zynerba Pharmaceuticals is hot or not.
By Olga Arara-Kimani, Regional Head, Corporate Affairs and Brand & Marketing Introduction Mobilising support for female...
The theme for October Transport Month 2020 is Smart Mobility. Smart Mobility is an innovative way of getting around. it is the...
After years of having served as a senior communications practitioner, I’ve learned that the most important attribute of any effective communicator is...
Subscribe to our newsletter
Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox